With $20m in new seed funding, Synthetic Design Lab is stepping out of stealth mode to advance novel antibody-drug conjugates (ADCs) based on its novel SYNTHBODY therapeutic platform against a range of cancer indications.
The San Francisco-based company, founded by CEO Daniel Chen, a physician and scientist in the cancer immunotherapy and protein engineering field, is backed by multiple investors including Playground Global and Godfrey
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?